RAMOT at Tel Aviv University Ltd. posted this:Immunotherapy for Stroke and Cognition in a Cerebral Amyloid Angiopathy Animal ModelCerebral amyloid angiopathy (CAA) is due to amyloid accumulation in the vessel walls leading to hemorrhagic stroke, and cognitive impairment. There are no available treatments to specifically reduce the risk of CAA. In this research we aim to assess brain tissue damage and cognitive impairment resulting from CAA in animal model and to investigate a novel approach to immune therapy. Methods: We have shown that nasal vaccination with a proteosome adjuvant (Protollin) that is well tolerated in humans, decreases amyloid plaques in an Alzheimer’s disease mouse model. It was recently reported that an overexpression of TGF-?1 under the control of an astrocyte promoter GFAP in mice results in CAA. TGF-?1 mice were nasally treated with Protollin on a weekly basis starting at the age of 13 months for three months. Following treatment animals were subjected for MRI and cognition analysis. Results: Here we show that nasal Protollin activates perivascular macrophage and potently decreases vascular amyloid in TGF-?1 mice. Using MRI we found that while PBS treated animals showed a significant enlargement of the lateral ventricles area, Protollin prevents further brain damage and prevents pathological changes in the blood-brain barrier. Vascular risk factors have been found to be associated with vascular dementia. Using an object recognition test and Y-maze, we found significant improvement in cognition with the Protollin treated group. Interpretation :Our study demonstrates that activation of macrophages by Protollin is a novel approach to reduce microhemorrhage, prevent stroke and improve cognition in a model of cerebral amyloid angiopathy. Project ID : 10-2011-259
uacoopera posted this:Fluorescent compounds, methods of manufacturing and uses thereofA group of researchers from a Portuguese university developed a family of new fluorophores to be used in biological imaging, either in cells or in entire organisms, in fluorescence microscopy techniques, including live cell imaging. The fluorophores are not toxic to cells and organisms, and light up cells by binding to organelles such as the Golgi apparatus, nucleus, and particularly lipid droplets. Importantly, the fluorophores change color with the polarity of the environment. The university is looking for companies that would be interested in developing this technology further through partnership, or in commercializing the probes through licensing or acquisition of the patent.
JPT Peptide Technologies posted this:Custom Peptide SynthesisJPT Peptide Technologies has a substantial, long-standing expertise in custom peptide synthesis services, providing custom peptides with highest quality for even complex or unusual peptide sequences. If you would like to order a quality peptide synthesis service using regulated processes, choose JPT! Furthermore, our peptide synthesis service has a very high success rate (over 99%) as JPT has developed the know-how to choose and optimize the appropriate synthesis method for each peptide. We go the extra mile to get your peptides done!
Creative Proteomics posted this:Proteomic ServiceCreative Proteomics specializes in a full range of services to support various proteome-related researches from identification of single proteins to large-scale proteomic studies. We have one of the most advanced proteomics platforms in the world and our staff scientists are experienced proteomics professionals.
Research InstituteView Profile
Germans Trias i Pujol Health Sciences Research Institute posted this:Innovative device for electro-mechanical stimulation for tissue engineering applicationsThe device presented enables the combination of both electrical and mechanical stimulation either independently or simultaneously. The mechanical stimulation is performed with a non-invasive and aseptic novel approach. A sterile, single use device is placed into a standard culture plate. The cells are seeded in a volume contained in the central area of the device, which goes through mechanical stimulation thanks to the embedded magnets and the external magnetic field.
Centre Technology Transfer CITTRU posted this:New method for efficient isolation of microbial DNA from bloodThe method of the invention is a solution that allows the simultaneous isolation of microbial DNA from the blood. In this method the isolation is carried out by compilation of enzymatic, mechanical and thermal lysis. This approach enables to obtain DNA from all types of organisms, irrespective of the structure of the cells.The obtained precipitate is subjected to further preparations, using a commercial DNA isolation kit according to the protocol provided by the manufacturer's procedure. The procedure results in obtaining the DNA ready for further stages of the analysis, e.g. performing a PCR reaction to detect fungi. The most important and most difficult problem in the treatment of bloodstream infections, determining the effectiveness of therapy and, consequently, the cost and time of hospitalization, is the effective diagnosis of factors responsible for the systemic inflammatory response in the course of sepsis. Determination of etiologic factors allows for selection of appropriate antibiotic therapy. The material subjected to diagnostic testing is blood taken from the patient showing clinical signs of sepsis. Currently, the "gold standard" diagnostic method is testing for microbial growth after inoculation in culture media specific to selected pathogen groups. This method is relatively simple and inexpensive, but also time-consuming – results can be available as late as in 5 days. Moreover, identification of pathogens with this method often fails due to low sensitivity; microbial growth can be detected in only about 15-20% of the cultures.
Creative Proteomics posted this:2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARDCreative Proteomics provides a full range of drug development services, including Molecular Biology, Biochemistry, Systems Biology, Organic Chemistry, Genomics, Bioinformatics, Structural Biology, Preclinical and Clinical studies. Please contact us to know more about 2,6-DIBDE (BDE-10) 50 UG/ML IN NONANE UNLABELED CERTIFIED STANDARD!
Creative Peptides posted this:Catalog Peptides-Teduglutide cas 197922-42-2Creative Peptides is specialized in the process development and the manufacturing of bioactive peptides. We offer custom peptide synthesis, process development, GMP manufacturing as well as catalog products. We provide Teduglutide. More information please visit the website:http://www.creative-peptides.com/product/teduglutide-item-m3412132-21367.html
RAMOT at Tel Aviv University Ltd. posted this:Novel Anti Bacterial DrugTwo non-toxic short peptides were conjugated to form a novel drug candidate. One of the peptides is a polymyxin-B or polymyxin-E analog (PMBN or PMEN, respectively) while the other is an immune cell chemotactic peptide (fMLF). The resultant new drug candidates (PMBN-fMLF or PMEN-fMLF) exhibit three antimicrobial activities: (a) it binds specifically to gram negative bacteria, thus enhancing penetration of antibiotics into the bacteria and (b) it promotes bacterial killing by blood phagocytes and (c) It binds to free LPS in the blood thus reduces effect on patients. Project ID : 10-2007-98
RAMOT at Tel Aviv University Ltd. posted this:GSK-3 Peptide Inhibitors for the Treatment of CNS Related DisordersNovel Glycogen synthase kinase 3 (GSK-3) inhibitors were developed. These inhibitors are substrate competitors that interact specifically with the GSK-3 substrate binding site. GSK-3, like other protein kinases, has a common structurally conserved catalytic domain that comprises the ATP-binding loop. The great majority of reported inhibitors developed to date are ATP-competitive compounds; however, such inhibitors demonstrate limited specificity, as the ATP-binding pocket is highly conserved among protein kinases. In contrast, the substrate binding site is more specific, and thus targeting inhibitors toward this domain yields more specific compounds. The strategy is based on exploiting the unique recognition motif of GSK-3 which comprises a phosphorylated residue and using molecular and computational analyses. Project ID : 10-2011-132
RAMOT at Tel Aviv University Ltd. posted this:Improved Calcitonin-based TherapeuticsThe aggregation site on human calcitonin has been identified, paving the way for development of specific inhibitors of calcitonin amyloid fibril formation. Such inhibitors will enable development of improved calcitonin therapeutics as well as greatly facilitate in vitro calcitonin manipulations. Project ID : 10-2007-103
RAMOT at Tel Aviv University Ltd. posted this:Novel markers for the identification and isolation of stem and progenitor cellsA series of novel markers: (1) chromatin remodeling protein factor termed (CHD9/CReMM), (2) A cell adhesion protein termed (SVEP1), (3) A kinesin protein termed (MS-KIF18A), (4) RNA processing factor (SRRF/hNRNP-L) have been developed as novel markers for the identification and isolation of stem and progenitor cells. Project ID : 10-2007-104
RAMOT at Tel Aviv University Ltd. posted this:Targeted filamentous bacteriophages as therapeutic agentsTargeted drug-carrying filamentous bacteriophages have been developed as a novel therapeutic approach for the treatment of infectious disease and cancer. The phages are genetically-modified to display an antibody or a targeting peptide as a targeting moiety on their surface and are used to deliver a cytotoxic drug to the target. The drug is linked to the phages by means of chemical conjugation through a labile linker subject to controlled release. In the conjugated state the cytotoxic drug is devoid of cytotoxic activity and is activated following its dissociation from the targeting phage at the target site in a temporally and spatially controlled manner. Project ID : 2-2008-23
RAMOT at Tel Aviv University Ltd. posted this:Novel ALS biomarkers:Towards diagnostics and potential therapyWe have identified ALS-specific biomarker candidate genes that are differentially expressed in blood and bone marrow samples from ALS patients. These biomarkers can be used for ALS diagnosis. Most importantly, these biomarkers can be used as targets for screening and identifying lead compounds for the treatment of ALS. Project ID : 10-2009-82